Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBIT: 2009-2024

Historic EBIT for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $93.1 million.

  • Ironwood Pharmaceuticals' EBIT rose 194.45% to $75.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $123.2 million, marking a year-over-year increase of 24.15%. This contributed to the annual value of $93.1 million for FY2024, which is 109.85% up from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' EBIT is $93.1 million, which was up 109.85% from -$945.4 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' EBIT registered a high of $250.3 million during FY2022, and its lowest value of -$945.4 million during FY2023.
  • Moreover, its 3-year median value for EBIT was $93.1 million (2024), whereas its average is -$200.7 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' EBIT crashed by 477.66% in 2023 and then spiked by 109.85% in 2024.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' EBIT stood at $142.9 million in 2020, then skyrocketed by 62.49% to $232.3 million in 2021, then increased by 7.78% to $250.3 million in 2022, then slumped by 477.66% to -$945.4 million in 2023, then spiked by 109.85% to $93.1 million in 2024.